Immunotherapy for gynaecological malignancies.

Abstract

Gynaecological malignancies, excluding breast cancer, cause approximately 25,000 deaths yearly among women in the US. Therefore, novel approaches for the prevention or treatment of these diseases are urgently required. In the case of cervical cancer, human papillomavirus (HPV) xenoantigens are readily recognised by the immune system, and their targeting has shown great promise in preclinical models of therapeutic vaccination and in clinical studies of preventative vaccination. A growing body of evidence indicates that ovarian cancer is also immunogenic and can thus be targeted through immunotherapy. This review outlines the principles and problems of immunotherapy for cervical and ovarian cancer, including the authors' personal assessment.

• Authors: George Coukos, Jose R Conejo-Garcia, Richard B S Roden, T-C Wu
• Journal: Expert opinion on biological therapy (Expert Opin Biol Ther) Vol. 5 Issue 9 Pg. 1193-210 (Sep 2005) ISSN: 1744-7682 [Electronic] England
• PMID: 16120050 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S., Review)

Chemical References

• Antigens, Heterophile
• Antigens, Neoplasm
• Cancer Vaccines
• Cytokines
• Vaccines, Attenuated
• Viral Vaccines

Topics

• Adoptive Transfer
• Animals
• Antigens, Heterophile (immunology)
• Antigens, Neoplasm (immunology)
• Cancer Vaccines (therapeutic use)
• Clinical Trials as Topic
• Cytokines
• Drug Evaluation, Preclinical
• Female
• Genital Neoplasms, Female (immunology, prevention & control, therapy)
• Humans
• Immunotherapy (methods)
• Lymphocytes, Tumor-Infiltrating (immunology, transplantation)
• Ovarian Neoplasms (immunology, prevention & control, therapy)
• Papillomaviridae (immunology)
• T-Lymphocytes, Regulatory
• Uterine Cervical Neoplasms (immunology, prevention & control, therapy)
• Vaccines, Attenuated (therapeutic use)
• Viral Vaccines (therapeutic use)